Mitchell Chan currently works at Avalo Therapeutics, Inc., as Independent Director from 2021, Maryland Technology Council, as Director from 2020, and REGENXBIO, Inc., as Executive VP, Chief ...

REGENXBIO (NASDAQ:RGNX) announced on Monday the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250M with Healthcare Royalty (HCRX). This agreement monetizes select ...

$150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher ...

The FDA granted REGENXBIO's BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of November 9, 2025. Logo for NS Pharma, Inc. (PRNewsfoto/NS Pharma, Inc.) In ...

Shares of RGNX opened at $6.67 on Tuesday. The company has a 50-day moving average of $7.61 and a two-hundred day moving average of $9.50. The stock has a market cap of $330.47 million, a P/E ...

Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately ...

Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 ...

In the latest quarter, 4 analysts provided ratings for Regenxbio (NASDAQ:RGNX), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

Jan 5 (Reuters) - Sarepta Therapeutics (SRPT.O), opens new tab convinced a Delaware federal court on Friday to end a patent lawsuit filed by biotech company Regenxbio (RGNX.O), opens new tab and ...

The latest price target for Regenxbio (NASDAQ:RGNX) was reported by Goldman Sachs on April 17, 2025. The analyst firm set a price target for $12.00 expecting RGNX to rise to within 12 months (a ...

REGENXBIO stock (NASDAQ: RGNX) declined by 20% yesterday, while it is down 26% in the last ten trading days. In comparison, the broader S&P500 index declined by 1.4% over the same period ...

Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the development of RGX314 for wet AMD. RGX202 is the hidden asset ...